Nurix Therapeutics
NRIX
22.73
+0.13
+0.58%
Nurix Therapeutics
US · NRIX
#2679 by market cap
Listed 2020
22.73
+0.13
+0.58%
Live - 5344 symbols - heartbeat 242s ago
· 2026-10-08 08:44
Pre-market
22.66
-0.31%
After-hours
22.73
0.00%
- Market cap
- 2.36B
- P/E (TTM)i
- -6.57
- P/Bi
- 5.86
- EPSi
- -3.05
- Div yieldi
- 0.00%
- 52W posi
- 71%
Reader sentiment
Are you bullish or bearish on NRIX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 7.09, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +53.95% YoY
Margins
- Operating margin
- -340.16%
- Net margin
- -314.90%
Key ratios & quality
- Altman Z-Scorei
- 7.09
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 37.45M | 31.12M | 17.82M | 29.75M | 38.63M | 76.99M | 54.55M | 83.98M |
| Gross profit | -- | -- | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 6.67M | 8.33M | 16.31M | 31.20M | 38.00M | 42.90M | 45.94M | 52.74M |
| Research & development | 40.51M | 45.03M | 66.49M | 116.43M | 184.50M | 189.15M | 221.63M | 316.90M |
| Operating profit | -9.74M | -22.24M | -64.98M | -117.89M | -183.87M | -155.06M | -213.03M | -285.67M |
| Pretax profit | -8.92M | -21.46M | -63.78M | -117.06M | -180.36M | -143.95M | -193.30M | -263.70M |
| Tax | 507.00K | 239.00K | -20.54M | 131.00K | 0 | 0 | 270.00K | 760.00K |
| Net profit | -9.43M | -21.70M | -43.24M | -117.19M | -180.36M | -143.95M | -193.57M | -264.46M |
| Basic EPS | -1 | -1 | -3 | -3 | -4 | -3 | -3 | -3 |
| Diluted EPS | -0.59 | -1.04 | -2.76 | -2.73 | -3.71 | -2.65 | -2.88 | -3.05 |
| Line item | 2025-02 | 2025-05 | 2025-08 | 2025-11 | 2026-02 | 2026-05 |
|---|---|---|---|---|---|---|
| Revenue | 18.45M | 44.06M | 7.89M | 13.58M | 6.25M | 9.04M |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 11.65M | 14.28M | 13.16M | 13.65M | 14.61M | 15.59M |
| Research & development | 69.66M | 78.10M | 86.12M | 83.02M | 84.14M | 87.65M |
| Operating profit | -62.86M | -48.32M | -91.39M | -83.10M | -92.50M | -94.20M |
| Pretax profit | -56.35M | -42.70M | -86.42M | -78.22M | -87.17M | -89.81M |
| Tax | -- | 760.00K | 0 | 0 | -- | -271.00K |
| Net profit | -56.35M | -43.46M | -86.42M | -78.22M | -87.17M | -89.54M |
| Basic EPS | -1 | -1 | -1 | -1 | -1 | -1 |
| Diluted EPS | -0.67 | -0.52 | -1.03 | -0.82 | -0.79 | -0.81 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 40.65M | 39.35M | 298.43M | 311.12M | 318.45M | 295.50M | 619.39M | 606.82M |
| Cash & ST investments | 39.04M | 37.72M | 281.15M | 295.72M | 309.14M | 287.91M | 609.58M | 592.94M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 45.40M | 44.05M | 396.34M | 476.77M | 416.76M | 355.60M | 669.34M | 688.14M |
| Total current liabilities | 32.83M | 16.14M | 44.54M | 66.26M | 70.66M | 86.96M | 95.85M | 86.47M |
| Short-term debt | -- | -- | -- | 3.85M | 5.53M | 7.49M | 8.01M | 2.82M |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 82,244,000.00 | 101,762,000.00 | 106,074,000.00 | 134,469,000.00 | 113,063,000.00 | 155,105,000.00 | 142,350,000.00 | 149,388,000.00 |
| Total equity | -36.85M | -57.71M | 290.27M | 342.30M | 303.70M | 200.49M | 526.99M | 538.75M |
| Retained earnings | -38.76M | -60.46M | -103.70M | -220.89M | -401.25M | -545.20M | -738.77M | -1.00B |
| Line item | 2025-02 | 2025-05 | 2025-08 | 2025-11 | 2026-02 | 2026-05 |
|---|---|---|---|---|---|---|
| Total current assets | 563.70M | 515.33M | 440.60M | 606.82M | 554.39M | 456.48M |
| Cash & ST investments | 549.68M | 485.78M | 428.83M | 592.94M | 540.73M | 443.53M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 615.04M | 591.56M | 522.47M | 688.14M | 636.13M | 535.54M |
| Total current liabilities | 89.99M | 75.61M | 82.35M | 86.47M | 92.20M | 72.02M |
| Short-term debt | 6.64M | 5.24M | 3.79M | 2.82M | 3.20M | 3.22M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 134,126,000.00 | 143,952,000.00 | 150,220,000.00 | 149,388,000.00 | 155,237,000.00 | 132,913,000.00 |
| Total equity | 480.92M | 447.60M | 372.25M | 538.75M | 480.89M | 402.63M |
| Retained earnings | -795.12M | -838.58M | -925.01M | -1.00B | -1.09B | -1.18B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -31.68M | 601.00K | -80.00K | -84.37M | -159.81M | -81.37M | -172.58M | -249.47M |
| Depreciation & amortization | 2.99M | 2.35M | 2.18M | 6.08M | 10.81M | 13.65M | 16.43M | 18.86M |
| Free cash flow | -33.27M | -1.05M | -4.63M | -90.03M | -172.05M | -89.77M | -181.86M | -263.47M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | 0 | 218.15M | 150.16M | 114.16M | 0 | 478.50M | 234.76M |
| Ending cash balance | 25.76M | 34.99M | 119.53M | 80.79M | 65.38M | 55.53M | 110.90M | 247.93M |
| Line item | 2025-02 | 2025-05 | 2025-08 | 2025-11 | 2026-02 | 2026-05 |
|---|---|---|---|---|---|---|
| Operating cash flow | -61.09M | -63.16M | -57.39M | -67.83M | -71.91M | -96.57M |
| Depreciation & amortization | 4.13M | 5.10M | 5.00M | 4.63M | 3.78M | 3.85M |
| Free cash flow | -64.57M | -65.84M | -60.10M | -72.96M | -72.96M | -98.51M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | 0 | 234.76M | 18.00M | 0 |
| Ending cash balance | 76.82M | 85.16M | 79.41M | 247.93M | 72.16M | 68.65M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -37.19 | -37.05 | -55.84 | -57.10 | -53.22 | -49.63 |
| ROA %i | -20.77 | -48.52 | -19.64 | -26.85 | -40.37 | -37.28 | -37.77 | -38.96 |
| ROIC %i | -- | -- | -37.89 | -35.77 | -54.80 | -56.72 | -54.25 | -49.82 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | -48.08 | -50.57 |
| EBIT margin %i | -26.01 | -71.46 | -364.66 | -396.26 | -476.01 | -201.41 | -390.52 | -340.16 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 1.24 | 2.44 | 6.70 | 4.70 | 4.51 | 3.40 | 6.46 | 7.02 |
| Quick ratioi | 1.19 | 2.34 | 6.57 | 4.56 | 4.38 | 3.31 | 6.36 | 6.86 |
| Debt / assetsi | -- | -- | 0.00 | 2.73 | 2.87 | 8.61 | 4.23 | 8.10 |
| LT debt / equityi | -- | -- | -- | 2.68 | 2.12 | 11.53 | 3.85 | 9.82 |
| Interest coveragei | -- | -- | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -7.38 | 7.47 | 62.87 | 22.40 | 29.55 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-02 | 2025-05 | 2025-08 | 2025-11 | 2026-02 | 2026-05 |
|---|---|---|---|---|---|---|
| ROE %i | -64.16 | -50.67 | -65.35 | -49.63 | -61.40 | -80.30 |
| ROA %i | -44.93 | -37.61 | -47.25 | -38.96 | -47.20 | -60.57 |
| ROIC %i | -64.11 | -50.34 | -63.19 | -49.82 | -60.37 | -75.16 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -408.87 | -260.75 | -319.32 | -340.16 | -439.26 | -982.37 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 6.26 | 6.82 | 5.35 | 7.02 | 6.01 | 6.34 |
| Quick ratioi | 6.11 | 6.68 | 5.21 | 6.86 | 5.86 | 6.16 |
| Debt / assetsi | 4.33 | 8.78 | 10.81 | 8.10 | 9.22 | 10.86 |
| LT debt / equityi | 4.16 | 10.43 | 14.16 | 9.82 | 11.53 | 13.64 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Discovery, development and commercialization of innovative targeted protein degradation medicines100.00%
Quote time 2026-10-08 08:44:15 · For reference only, not investment advice and not tailored to your situation.